CHRS Coherus BioSciences, Inc.

NASDAQ
$1.13

Coherus BioSciences, Inc. (CHRS) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.1% since its last earnings release on August 5, 2026.

Coherus BioSciences Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:28 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:30 PM ET
Earnings Whisper
-
vs ($0.22)
Rev est $16.06M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Coherus BioSciences, Inc.

Coherus BioSciences Inc is a late-stage clinical biologics platform company. The Company is engaged in developing biosimilar therapeutics.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.